Welcome to our dedicated page for Urogen Pharma news (Ticker: URGN), a resource for investors and traders seeking the latest updates and insights on Urogen Pharma stock.
UroGen Pharma Ltd (NASDAQ: URGN) is a clinical-stage biopharmaceutical leader developing novel non-surgical therapies for urothelial cancers through its proprietary sustained release technology. This page serves as the definitive source for verified company announcements, clinical trial updates, and financial disclosures.
Access real-time updates on URGN's innovative hydrogel-based treatments, including regulatory milestones and research developments. Our curated news collection features:
• Clinical trial progress for localized cancer therapies
• FDA submission updates and regulatory interactions
• Financial performance reports and earnings calls
• Strategic partnerships in uro-oncology innovation
Bookmark this page for direct access to primary source materials and expert analysis of URGN's pioneering work in non-invasive cancer treatment solutions. Check regularly for the latest developments in sustained-release drug delivery systems and their impact on urothelial cancer care standards.
UroGen Pharma Ltd. (Nasdaq: URGN) announced that the FDA has authorized an extension of the in-use period for JELMYTO (mitomycin) from 8 hours to 96 hours after reconstitution. This allows for greater logistical flexibility for healthcare providers and enhances access for patients with low-grade upper-tract urothelial cancer (LG UTUC). The new guidelines will streamline patient care and scheduling, aligning with UroGen's goal of improving treatment delivery.
UroGen Pharma (NASDAQ: URGN) has appointed Dr. Leana S. Wen to its Board of Directors, effective immediately. Dr. Wen is an emergency medicine physician and public health expert, currently a professor at George Washington University. Her experience includes serving as Baltimore's health commissioner, where she tackled significant health issues. UroGen's CEO, Liz Barrett, highlighted that Dr. Wen's expertise will enhance the company's mission in uro-oncology. With a focus on innovative treatments, UroGen aims to meet the unmet needs in the field.
UroGen Pharma Ltd. (Nasdaq: URGN) announced the grant of up to 43,300 inducement restricted stock units (RSUs) to 10 new employees as part of their employment. These RSUs will vest over three years, supporting the launch of Jelmyto® for treating pyelocalyceal solution and the company's ongoing pipeline development. This initiative aims to enhance their team to further innovate in the treatment of urothelial and specialty cancers, demonstrating UroGen's commitment to advancing therapeutic options for patients.
UroGen Pharma Ltd. (Nasdaq: URGN) announced its participation in two healthcare conferences in September: the H.C. Wainwright & Co. Annual Global Investment Conference on September 13 and the Ladenburg Thalmann Healthcare Conference on September 29. Both presentations will be accessible via webcasts on UroGen’s website, where replays will be available for 30 days. UroGen focuses on innovative treatments for urothelial and specialty cancers, leveraging proprietary technologies like RTGel™ for local therapies that enhance drug effectiveness.
UroGen Pharma reported second quarter 2022 net product revenue from Jelmyto of $16.6 million, marking a 22% increase from Q1 2022 and a 28% increase year-over-year.
The company reaffirmed its 2022 revenue guidance, expecting $70-$80 million in total. Clinical trials for UGN-102 are on track, with enrollment expected to complete by year-end 2022. The company is targeting cash flow break-even by 2025. However, a net loss of $26.7 million was reported for the quarter, while cash equivalents totaled $112.4 million as of June 30, 2022.
UroGen Pharma Ltd. (Nasdaq: URGN) will announce its Q2 2022 financial results on
UroGen Pharma Ltd. (Nasdaq: URGN) announced the grant of inducement restricted stock units (RSUs) and options to 16 new employees as part of their ongoing commercial launch of Jelmyto® and pipeline development. A total of 53,000 shares will be available through RSUs, while 12,000 shares are associated with options, both vesting over three years. These grants comply with Nasdaq rules, aimed at incentivizing new talent to enhance UroGen's capabilities in treating urothelial and specialty cancers.
UroGen Pharma Ltd. (Nasdaq: URGN) announces participation in two healthcare conferences: the H.C. Wainwright & Co. Global Investment Conference on May 25 at 11:00 a.m. ET and the Jefferies Healthcare Conference on June 9 at 1:00 p.m. ET. Webcasts for both events will be accessible on UroGen's website, with replays available for 30 days. UroGen focuses on developing innovative solutions for urothelial and specialty cancers, utilizing its proprietary RTGel™ technology for improved treatment options.
UroGen Pharma Ltd. (Nasdaq: URGN) presented new data at the 2022 American Urological Association annual meeting in New Orleans. The study highlights the effectiveness of the antegrade approach via nephrostomy tube for administering JELMYTO (mitomycin) in treating low-grade upper tract urothelial cancer. This method showed promising safety and efficacy data, demonstrating a complete response in 50% of patients. Although the study was retrospective and limited in size, it adds valuable real-world evidence to support treatment options for patients.
UroGen Pharma Ltd. (Nasdaq: URGN) will showcase data on JELMYTO® (mitomycin) for treating low-grade upper tract urothelial cancer at the 2022 AUA Annual Meeting in New Orleans, scheduled from May 13-16. Significant presentations will include findings from the Phase 2b OPTIMA II trial highlighting health-related quality of life impacts. JELMYTO is noted for being the only non-surgical treatment option. The presentations will be published in the June 2022 issue of The Journal of Urology.
FAQ
What is the current stock price of Urogen Pharma (URGN)?
What is the market cap of Urogen Pharma (URGN)?
